Accession Number : ADA613312


Title :   Cell-penetrating Bispecific Antibodies for Targeting Oncogenic Transcription Factors in Advanced Prostate Cancer


Descriptive Note : Annual rept. 30 Sep 2013-29 Sep 2014


Corporate Author : MEDICAL UNIV OF SOUTH CAROLINA CHARLESTON


Personal Author(s) : Lilly, Michael


Full Text : http://www.dtic.mil/get-tr-doc/pdf?AD=ADA613312


Report Date : Oct 2014


Pagination or Media Count : 9


Abstract : The goal of these studies is to develop and validate cell-penetrating bi-specific antibodies as an agent that can selectively inhibit the function of intracellular proteins. We have developed 3E10-AR441 bi-specific antibody to inhibit the function both ligand-dependent and independent forms of the androgen receptor (AR), key drivers of prostate carcinogenesis. Key accomplishments in this reporting period are the production of a prototype 3E10-AR441 bi-specific antibody, and demonstration of target engagement under denaturing and non-denaturing conditions, as well as in intact cell systems. The antibody inhibited the growth of prostate cancer cells. We will continue to characterize the biochemical lesions produced by this antibody, while developing higher affinity analogs with improved production characteristics.


Descriptors :   *ANTIBODIES , *PROSTATE CANCER , ANDROGENS , BIOCHEMISTRY , CELLS(BIOLOGY) , DEMONSTRATIONS , INHIBITION , PROTEINS , PROTOTYPES , RECEPTOR SITES(PHYSIOLOGY) , TRANSCRIPTION(GENETICS)


Subject Categories : Biochemistry
      Anatomy and Physiology
      Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE